Human Genome Sciences

PPD names VP for global product development

Monday, September 23, 2013

CRO PPD has appointed Gregory Dennis, M.D., vice president of global product development. Dennis will be therapeutic area head, providing medical and scientific expertise for rheumatology, immunology and inflammatory diseases.

[Read More]

Geron discontinues GRN100, cuts 43 workers

Wednesday, December 5, 2012

Geron, a Menlo Park, Calif.-based biopharmaceutical company developing first-in-class therapies for cancer, has discontinued development of GRN1005, its peptide-drug conjugate designed to treat cancers in the brain. Going forward, the company will focus on the development of imetelstat, its telomerase inhibitor, in hematologic myeloid malignancies and in patients with solid tumors that have short telomeres.

[Read More]

EntreMed names two to board of directors

Tuesday, February 7, 2012

EntreMed, a clinical-stage pharmaceutical company developing therapeutics for the treatment of cancer, has appointed Wei-Wu He, Ph.D, executive chairman of its board of directors, and Tak W. Mak, Ph.D, as member of the board of directors.

[Read More]